Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.

Can’t make the date? Still register to receive the webinar recording afterwards.

Genome Editing Webinar

Gene Editing On-Target Out Comes: Are Indels The Only Outcomes To Be Expected?

Wednesday, 26th August 2020 | 13:00 BST

Presented by Eric Paul Bennett, Associate Professor, Coppenhagen University, Senior Advisor, NovoNordisk

  • Survey of on-target outcomes to be expected after gene editing including, indels, translocations and large deletions.
  • Brief survey of the pro’s and con’s of the available gene editing outcome detection methodologies, including enzyme mismatch cleavage, digital PCR, NGS and IDAA.
  • Examples of the application of accurate and sensitive detection of complex gene editing induced indel outcomes in mammalian cells, tissues and whole organisms including plants, mosquitos and fish

Eric P. Bennett has obtained both his master degree in Biochemistry and Molecular Biology (MSc) and doctoral degree (Dr Med) from the University of Copenhagen. His research efforts at the Copenhagen Center for Glycomics, University of Copenhagen, have been concentrated in the field of Glycobiology where he 2 decades ago cloned and identified more than 30 human glycosyltransferase encoded genes (glycogenes).

For the last 9 years his efforts have been focused on ways of establishing precision-engineered isogenic cells lacking individual glycogenes. Using the recently emerged nuclease targeting technologies, such as ZFN, TALEN and CRISPR/Cas9 these efforts have among others led to establishment of novel methodologies that both improve the targeting and indel detection efficacy of precise gene targeting.

The methods and principles developed show great translational potential into the biotech and therapeutic genome targeting space

Next Generation Sequencing Webinar

Rapid And Comprehensive RNA-Seq Data Exploration And Visualisation For Unlimited Differential Datasets

Wednesday, 2nd September 2020 | 13:00 BST

Presented by John Cole, Bioinformatician (Immunology), University of Glasgow

  • The exploration, interpretation and visualisation stages of bulk RNA-seq are extremely time consuming and costly. Remarkably, little progress has been made towards its reduction in the last decade
  • Searchlight automates bulk RNA-seq exploration, interpretation and visualisation considerably further than has previously been possible, by assuming that most experiments can be simplified into a combination of pre-set workflows based on the experimental design
  • Resultantly it can save weeks and even months worth of time, labour and resources, per RNA-seq experiment

John studied genetics and bioinformatics at the University of Glasgow before working as a Computational Biologist for Cancer Research UK, investigating the epigenetics of Acute Myeloid Leukaemia and Ageing. In particular he has shown that genetic, dietary and small molecule mediated healthy ageing suppress a common set of age related methylome changes. He now works for the GLAZgo Discovery Centre a collaboration between the University of Glasgow and AstraZeneca. His current role focuses on the transcriptomics, epigenetics and metabolomics of Respiratory and Rheumatoid disease and aims to be translational. He is currently using lessons learned in time and resource efficiency to develop novel software for making bulk RNA-seq exploration, interpretation and visualisation considerably faster, more convenient and less resource heavy (

Looking for more?

All of our past webinars are available for download from our Content HUB, as well as Market Industry Reports, Q&A Sessions, Newsletters and much more.

Live Webinar

Genomic Testing Strategies For Research Through To Clinical Studies: Profiling Of Genomics From NeoGenomics' Perspective

As genomic technologies develop and mature, adoption moves from the research environment into the clinical setting.  Previously, where Sanger and qPCR were the most rational choices to commercialize a diagnostic, NGS has become the biomarker testing methodology of choice.  Additionally, other emerging technologies and platforms like NanoString are finding their way into clinical trials as well as routine diagnostics.  With advances in technology, biomarker testing strategies have also evolved with a trend toward higher order multiplexed technologies as well as cross modality testing from a single sample to understand correlations between DNA, RNA and protein markers.  More data may be over burdensome to analyze, while a focused assay may miss an opportunity for collecting potentially valuable data.  Without a straightforward “rule of thumb” for which genomics technology to use when, thoughtful consultation is required.  This presentation will discuss the various factors and consideration points for choosing a genomic biomarker testing strategy to support biomarker projects.

Presented by James Yen, Senior Scientific Manager, CDx Programs, NeoGenomics

Thursday, 25 June 2020 | 15:30 BST